参桂胶囊联合比索洛尔治疗慢性心力衰竭的临床研究  

Clinical study on Shengui Capsules combined with bisoprolol in treatment of chronic heart failure

作　　者：李松林 谷朝华 马涛 姚先丽 LI Song-lin;GU Chao-hua;MA Tao;YAO Xian-li(Department of Cardiovascular Medicine,the First People's Hospital of Xiangcheng,Zhoukou 466200,China;Department of Neurology,Henan Provincial Hospital of TCM,Zhengzhou 450000,China)

机构地区：[1]项城市第一人民医院心血管内科,河南周口466200 [2]河南省中医院神经内科,河南郑州450000

出　　处：《现代药物与临床》2023年第1期101-104,共4页Drugs & Clinic

基　　金：河南省医学科技攻关计划项目(2018020808)。

摘　　要：目的 探讨参桂胶囊联合富马酸比索洛尔片治疗慢性心力衰竭的临床疗效。方法 选取2020年4月—2022年3月在项城市第一人民医院就诊的77例慢性心力衰竭患者,根据随机数字表法分为对照组(38例)和治疗组(39例)。对照组患者口服富马酸比索洛尔片,1片/次,1次/d。治疗组在对照组治疗的基础上口服参桂胶囊,4粒/次,3次/d。两组患者共治疗1个月。观察两组的临床疗效,比较两组患者的心功能指标、心衰计分系统(LEE)评分和血清因子水平。结果 治疗后,治疗组的总有效率(94.87%)明显高于对照组(78.95%)(P<0.05)。治疗后,两组的左心室射血分数(LVEF)明显升高,左室后壁厚度(LVPW)、左心房压力(LAP)明显降低(P<0.05);治疗组的LVEF明显高于对照组,LVPW、LAP明显低于对照组(P<0.05)。治疗后,两组的LEE评分明显降低(P<0.05),且治疗组LEE评分明显低于对照组(P<0.05)。治疗后,两组的B型钠尿肽(BNP)、半乳糖凝集素3(Gal-3)、结缔组织生长因子(CTGF)水平低于治疗前,且治疗组的BNP、Gal-3、CTGT水平低于对照组,差异有统计学意义(P<0.05)。结论 参桂胶囊联合比索洛尔治疗慢性心力衰竭的疗效确切,能改善心功能、控制心衰病情,调节BNP、Gal-3、CTGT水平。Objective To investigate the clinical efficacy of Shengui Capsules combined with Bisoprolol Fumarate Tablets in treatment of chronic heart failure. Methods Patients(77 cases) with chronic heart failure in First People’s Hospital of Xiangcheng from April 2020 to March 2022 were divided into control group(38 cases) and treatment group(39 cases) according to random number table method. Patients in the control group were po administered with Bisoprolol Fumarate Tablets, 1 tablet/time, once daily. Patients in the treatment group were po administered with Shengui Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 1 month. After treatment, the clinical efficacies were evaluated, and the cardiac function indexes, LEE scores, and serum factors level in two groups were compared. Results After treatment, the total effective rate(94.87%) of the treatment group was significantly higher than 78.95% of the control group(P<0.05). After treatment, LVEF in two groups was significantly increased, but LVPW and LAP in two groups were significantly decreased(P<0.05). LVEF of the treatment group was significantly higher than that of the control group, but LVPW and LAP were significantly lower than those of the control group(P <0.05). After treatment, LEE score of two groups was significantly lower(P<0.05), and LEE score of the treatment group was significantly lower than that of the control group(P<0.05). After treatment, the levels of BNP, Gal-3, and CTGT in two groups were lower than those before treatment, and the serum factors levels in the treatment group were lower than those in the control group(P <0.05). Conclusion Shengui Capsules combined with Bisoprolol Fumarate Tablets has clinical curative effect in treatment of chronic heart failure, can improve cardiac function, control the condition of heart failure, and regulate the levels of BNP, Gal-3 and CTGT.

关 键 词：参桂胶囊 富马酸比索洛尔片 慢性心力衰竭 左心室射血分数 LEE评分 B型钠尿肽 半乳糖凝集素3 

分 类 号：R972[医药卫生—药品]